DE/EN
  • Deutsch
  • English
  • About us
    • His­tory
    • Who we are
    • Man­age­ment
    • Found­a­tion
    • Super­vis­ory Board
    • Sci­entific Advis­ory Board
    • Sci­entific Advisors
  • Research
    • Pro­jects
      • Uni­S­ens
    • Dis­eases
    • Tech­no­lo­gies
    • Pub­lic­a­tions
  • Devel­op­ment
    • Alzheimer anti­bod­ies
    • Immune ther­apies
    • Lipid nan­o­particles
  • Ser­vices
    • Gen­ome Editing
    • Human iPS cells
    • Meas­ure­ments to accom­pany (pre-)clinical studies
    • Reg­u­lat­ory services
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact
REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE REPROGRAM - REFINE - REGENERATE
  • About us
    • His­tory
    • Who we are
    • Man­age­ment
    • Found­a­tion
    • Super­vis­ory Board
    • Sci­entific Advis­ory Board
    • Sci­entific Advisors
  • Research
    • Pro­jects
      • Uni­S­ens
    • Dis­eases
    • Tech­no­lo­gies
    • Pub­lic­a­tions
  • Devel­op­ment
    • Alzheimer anti­bod­ies
    • Immune ther­apies
    • Lipid nan­o­particles
  • Ser­vices
    • Gen­ome Editing
    • Human iPS cells
    • Meas­ure­ments to accom­pany (pre-)clinical studies
    • Reg­u­lat­ory services
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact

Archives

Monthly Archive for: "December, 2019"
Home » Archives for December 2019
sTREM2, a poten­tial bio­marker in AD
0
By p564569
In Neurodegenerative diseases, Publications
Posted 28. December 2019

sTREM2, a poten­tial bio­marker in AD

sTREM2 correlates with microglia activation, and higher CSF sTREM2 levels can be linked to reduced cognitive decline and slower rates of Plaque accumulation in AD patients.


READ MORE
  • +49 89 356 475 400
  • info@isarbioscience.de
NAV­IG­A­TION
  • About us
  • Back­ground
  • Research
  • Ser­vices
  • Co-Oper­­a­­tions
  • News
  • Jobs
  • Con­tact
© 2022 ISAR Bioscience. All rights reserved.
  • Cookie Set­tings
  • Pri­vacy Policy
  • Legal Inform­a­tion
  • Deutsch
back BACK